http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 13 Feb 2026 17:23:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IO+Biotech%2C+Inc.++++++++++For%3A+Feb+12/26002101.html si-local-file:///var/storage/secattach/20260213/26002101.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IO+Biotech%2C+Inc.++++++++++For%3A+Feb+12/26002101.html Fri, 13 Feb 2026 17:23:00 -0500 IOBT O.53121624 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IO+Biotech%2C+Inc.++++++++++For%3A+Feb+12/26002101.html si-local-file:///var/storage/secattach/20260213/26002101.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IO+Biotech%2C+Inc.++++++++++For%3A+Feb+12/26002101.html Fri, 13 Feb 2026 17:23:00 -0500 IOBT O.53121624 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Chernett+Jorey/26001819.html si-local-file:///var/storage/secattach/20260213/26001819.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Chernett+Jorey/26001819.html Fri, 13 Feb 2026 17:06:00 -0500 IOBT O.53121624 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Chernett+Jorey/26001819.html si-local-file:///var/storage/secattach/20260213/26001819.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Chernett+Jorey/26001819.html Fri, 13 Feb 2026 17:06:00 -0500 IOBT O.53121624 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./25961626.html si-local-file:///var/storage/secattach/20260206/25961626.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./25961626.html Fri, 06 Feb 2026 16:10:00 -0500 IOBT O.53121624 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./25961626.html si-local-file:///var/storage/secattach/20260206/25961626.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Point72+Asset+Management%2C+L.P./25961626.html Fri, 06 Feb 2026 16:10:00 -0500 IOBT O.53121624 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IO+Biotech%2C+Inc.++++++++++For%3A+Jan+30/25924290.html si-local-file:///var/storage/secattach/20260130/25924290.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IO+Biotech%2C+Inc.++++++++++For%3A+Jan+30/25924290.html Fri, 30 Jan 2026 16:54:00 -0500 IOBT O.53121624 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IO+Biotech%2C+Inc.++++++++++For%3A+Jan+30/25924290.html si-local-file:///var/storage/secattach/20260130/25924290.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IO+Biotech%2C+Inc.++++++++++For%3A+Jan+30/25924290.html Fri, 30 Jan 2026 16:54:00 -0500 IOBT O.53121624 http://www.streetinsider.com/Corporate+News/IO+Biotech+engages+Raymond+James%2C+implements+workforce+reduction/25919986.html <p>IO Biotech Inc. (NASDAQ: IOBT) announced it has retained Raymond James & Associates Inc. as exclusive financial advisor to assist in exploring strategic alternatives, according to a company statement.</p><p>The clinical-stage biopharmaceutical company also said it is implementing cost-containment and cash conservation measures, including a significant workforce reduction, to lower operating expenses during the strategic review process.</p><p>IO Biotech develops immune-modulatory therapeutic cancer vaccines using its T-win platform technology. The company is based in Copenhagen, Denmark, with U.S. headquarters in New York.</p><p>The workforce reduction represents part of broader efforts to preserve cash while the company evaluates potential strategic options. The company had http://www.streetinsider.com/Corporate+News/IO+Biotech+engages+Raymond+James%2C+implements+workforce+reduction/25919986.html Fri, 30 Jan 2026 08:05:23 -0500 IOBT http://www.streetinsider.com/Press+Releases/IO+Biotech+Provides+Corporate+Update/25919984.html <ul type="disc"><li style="list-style-position:inside; text-align:center;">Raymond James engaged as financial advisor</li><li style="list-style-position:inside; text-align:center;">Reduction in force implemented <br/></li></ul> <p align="justify">NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James &amp; Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives.</p> <p align="justify">The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company’s workforce, to reduce operating expenses while the http://www.streetinsider.com/Press+Releases/IO+Biotech+Provides+Corporate+Update/25919984.html Fri, 30 Jan 2026 08:05:00 -0500 A.26391080 IOBT O.00030728 O.53121624 http://www.streetinsider.com/Press+Releases/IO+Biotech+Provides+Corporate+Update/25919984.html <ul type="disc"><li style="list-style-position:inside; text-align:center;">Raymond James engaged as financial advisor</li><li style="list-style-position:inside; text-align:center;">Reduction in force implemented <br/></li></ul> <p align="justify">NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James &amp; Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives.</p> <p align="justify">The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company’s workforce, to reduce operating expenses while the http://www.streetinsider.com/Press+Releases/IO+Biotech+Provides+Corporate+Update/25919984.html Fri, 30 Jan 2026 08:05:00 -0500 A.26391080 IOBT O.00030728 O.53121624 http://www.streetinsider.com/Press+Releases/IO+Biotech+Provides+Corporate+Update/25919984.html <ul type="disc"><li style="list-style-position:inside; text-align:center;">Raymond James engaged as financial advisor</li><li style="list-style-position:inside; text-align:center;">Reduction in force implemented <br/></li></ul> <p align="justify">NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James &amp; Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives.</p> <p align="justify">The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company’s workforce, to reduce operating expenses while the http://www.streetinsider.com/Press+Releases/IO+Biotech+Provides+Corporate+Update/25919984.html Fri, 30 Jan 2026 08:05:00 -0500 A.26391080 IOBT O.00030728 O.53121624 http://www.streetinsider.com/Press+Releases/IO+Biotech+Provides+Corporate+Update/25919984.html <ul type="disc"><li style="list-style-position:inside; text-align:center;">Raymond James engaged as financial advisor</li><li style="list-style-position:inside; text-align:center;">Reduction in force implemented <br/></li></ul> <p align="justify">NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James &amp; Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives.</p> <p align="justify">The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company’s workforce, to reduce operating expenses while the http://www.streetinsider.com/Press+Releases/IO+Biotech+Provides+Corporate+Update/25919984.html Fri, 30 Jan 2026 08:05:00 -0500 A.26391080 IOBT O.00030728 O.53121624 http://www.streetinsider.com/Globe+Newswire/IO+Biotech+Provides+Corporate+Update/25919984.html <ul type="disc"><li style="list-style-position:inside; text-align:center;">Raymond James engaged as financial advisor</li><li style="list-style-position:inside; text-align:center;">Reduction in force implemented <br/></li></ul> <p align="justify">NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James &amp; Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives.</p> <p align="justify">The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company’s workforce, to reduce operating expenses while the http://www.streetinsider.com/Globe+Newswire/IO+Biotech+Provides+Corporate+Update/25919984.html Fri, 30 Jan 2026 08:05:00 -0500 A.26391080 IOBT O.00030728 O.53121624 http://www.streetinsider.com/Globe+Newswire/IO+Biotech+Provides+Corporate+Update/25919984.html <ul type="disc"><li style="list-style-position:inside; text-align:center;">Raymond James engaged as financial advisor</li><li style="list-style-position:inside; text-align:center;">Reduction in force implemented <br/></li></ul> <p align="justify">NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James &amp; Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives.</p> <p align="justify">The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company’s workforce, to reduce operating expenses while the http://www.streetinsider.com/Globe+Newswire/IO+Biotech+Provides+Corporate+Update/25919984.html Fri, 30 Jan 2026 08:05:00 -0500 A.26391080 IOBT O.00030728 O.53121624 http://www.streetinsider.com/Globe+Newswire/IO+Biotech+Provides+Corporate+Update/25919984.html <ul type="disc"><li style="list-style-position:inside; text-align:center;">Raymond James engaged as financial advisor</li><li style="list-style-position:inside; text-align:center;">Reduction in force implemented <br/></li></ul> <p align="justify">NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James &amp; Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives.</p> <p align="justify">The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company’s workforce, to reduce operating expenses while the http://www.streetinsider.com/Globe+Newswire/IO+Biotech+Provides+Corporate+Update/25919984.html Fri, 30 Jan 2026 08:05:00 -0500 A.26391080 IOBT O.00030728 O.53121624 http://www.streetinsider.com/Globe+Newswire/IO+Biotech+Provides+Corporate+Update/25919984.html <ul type="disc"><li style="list-style-position:inside; text-align:center;">Raymond James engaged as financial advisor</li><li style="list-style-position:inside; text-align:center;">Reduction in force implemented <br/></li></ul> <p align="justify">NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that it has retained Raymond James &amp; Associates, Inc. to serve as exclusive financial advisor to assist the company in its previously announced exploration of strategic alternatives.</p> <p align="justify">The company also announced that it is implementing cost-containment and cash conservation measures, including a significant reduction of the company’s workforce, to reduce operating expenses while the http://www.streetinsider.com/Globe+Newswire/IO+Biotech+Provides+Corporate+Update/25919984.html Fri, 30 Jan 2026 08:05:00 -0500 A.26391080 IOBT O.00030728 O.53121624 http://www.streetinsider.com/Downgrades/Piper+Sandler+Downgrades+IO+Biotech+%28IOBT%29+to+Neutral/25889094.html <p>Piper Sandler analyst Allison M. Bratzel downgraded IO Biotech (NASDAQ: IOBT) from Overweight to Neutral with a price target of $0.50 (from $3.00).</p><p>The analyst comments: "We are moving to Neutral rated on IOBT shares following the announcement that the company intends to explore a range of strategic opportunities to maximize shareholder value – of which could include a merger, business combination, a sale of assets, or liquidation/dissolution. Few additional details were provided in the press release, and the company does not expect to provide additional updates until the BoD deems disclosure appropriate. While we believe the underlying science behind the http://www.streetinsider.com/Downgrades/Piper+Sandler+Downgrades+IO+Biotech+%28IOBT%29+to+Neutral/25889094.html Mon, 26 Jan 2026 00:32:04 -0500 IOBT http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+Downgrades+IO+Biotech+%28IOBT%29+to+Neutral/25889094.html <p>Piper Sandler analyst Allison M. Bratzel downgraded IO Biotech (NASDAQ: IOBT) from Overweight to Neutral with a price target of $0.50 (from $3.00).</p><p>The analyst comments: "We are moving to Neutral rated on IOBT shares following the announcement that the company intends to explore a range of strategic opportunities to maximize shareholder value – of which could include a merger, business combination, a sale of assets, or liquidation/dissolution. Few additional details were provided in the press release, and the company does not expect to provide additional updates until the BoD deems disclosure appropriate. While we believe the underlying science behind the http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+Downgrades+IO+Biotech+%28IOBT%29+to+Neutral/25889094.html Mon, 26 Jan 2026 00:32:04 -0500 IOBT http://www.streetinsider.com/Downgrades/Piper+Sandler+Downgrades+IO+Biotech+%28IOBT%29+to+Neutral/25889095.html <p>Piper Sandler analyst Allison M. Bratzel downgraded IO Biotech (NASDAQ: IOBT) from Overweight to Neutral with a price target of $0.50 (from $3.00).</p><p>The analyst comments: "We are moving to Neutral rated on IOBT shares following the announcement that the company intends to explore a range of strategic opportunities to maximize shareholder value – of which could include a merger, business combination, a sale of assets, or liquidation/dissolution. Few additional details were provided in the press release, and the company does not expect to provide additional updates until the BoD deems disclosure appropriate. While we believe the underlying science behind the http://www.streetinsider.com/Downgrades/Piper+Sandler+Downgrades+IO+Biotech+%28IOBT%29+to+Neutral/25889095.html Mon, 26 Jan 2026 00:32:04 -0500 IOBT http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+Downgrades+IO+Biotech+%28IOBT%29+to+Neutral/25889095.html <p>Piper Sandler analyst Allison M. Bratzel downgraded IO Biotech (NASDAQ: IOBT) from Overweight to Neutral with a price target of $0.50 (from $3.00).</p><p>The analyst comments: "We are moving to Neutral rated on IOBT shares following the announcement that the company intends to explore a range of strategic opportunities to maximize shareholder value – of which could include a merger, business combination, a sale of assets, or liquidation/dissolution. Few additional details were provided in the press release, and the company does not expect to provide additional updates until the BoD deems disclosure appropriate. While we believe the underlying science behind the http://www.streetinsider.com/Analyst+Comments/Piper+Sandler+Downgrades+IO+Biotech+%28IOBT%29+to+Neutral/25889095.html Mon, 26 Jan 2026 00:32:04 -0500 IOBT http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Novo+Holdings+AS/25888619.html si-local-file:///var/storage/secattach/20260123/25888619.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Novo+Holdings+AS/25888619.html Fri, 23 Jan 2026 19:05:00 -0500 IOBT O.53121624 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Novo+Holdings+AS/25888619.html si-local-file:///var/storage/secattach/20260123/25888619.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13DA++IO+Biotech%2C+Inc.+++++++++++++++++++++++Filed+by%3A+Novo+Holdings+AS/25888619.html Fri, 23 Jan 2026 19:05:00 -0500 IOBT O.53121624 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IO+Biotech%2C+Inc.++++++++++For%3A+Jan+21/25870812.html si-local-file:///var/storage/secattach/20260121/25870812.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IO+Biotech%2C+Inc.++++++++++For%3A+Jan+21/25870812.html Wed, 21 Jan 2026 06:06:00 -0500 IOBT O.53121624 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IO+Biotech%2C+Inc.++++++++++For%3A+Jan+21/25870812.html si-local-file:///var/storage/secattach/20260121/25870812.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++IO+Biotech%2C+Inc.++++++++++For%3A+Jan+21/25870812.html Wed, 21 Jan 2026 06:06:00 -0500 IOBT O.53121624